Goldman Sachs’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Goldman Sachs’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-61,400	Closed	-$7.49M	–	7036
2025 Q4	$7.49M	Sell	61,400 -30,000	-33%	-$3.44M	﹤0.01%	3363
2025 Q3	$9.16M	Buy	91,400 +30,000	+49%	+$2.7M	﹤0.01%	3047
2025 Q2	$5.09M	Sell	61,400 -200,000	-77%	-$16M	﹤0.01%	3392
2025 Q1	$21.2M	Sell	261,400 -1,067,400	-80%	-$95.4M	﹤0.01%	1974
2024 Q4	$120M	Buy	1,328,800 +1,207,800	+998%	+$117M	0.02%	712
2024 Q3	$12M	Sell	121,000 -950,000	-89%	-$93.3M	﹤0.01%	2544
2024 Q2	$99.3M	Buy	1,071,000 +982,000	+1,103%	+$88M	0.02%	802
2024 Q1	$8.45M	Sell	89,000 -950,000	-91%	-$88.2M	﹤0.01%	2630
2023 Q4	$92.8M	Buy	1,039,000 +118,000	+13%	+$8.76M	0.02%	828
2023 Q3	$67.3M	Buy	921,000 +201,000	+28%	+$16.1M	0.01%	937
2023 Q2	$59.9M	Sell	720,000 -230,000	-24%	-$19.2M	0.01%	974
2023 Q1	$72.4M	Sell	950,000 -243,800	-20%	-$20.2M	0.02%	828
2022 Q4	$99.1M	Buy	1,193,800 +150,000	+14%	+$12.1M	0.02%	726
2022 Q3	$82.8M	Buy	1,043,800 +502,000	+93%	+$42.3M	0.02%	787
2022 Q2	$40.2M	Buy	541,800 +200,000	+59%	+$15M	0.01%	1278
2022 Q1	$30.7M	Sell	341,800 -622,400	-65%	-$57.5M	0.01%	1702
2021 Q4	$108M	Buy	964,200 +553,100	+135%	+$66.7M	0.02%	772
2021 Q3	$51.7M	Buy	411,100 +318,500	+344%	+$41M	0.01%	1259
2021 Q2	$12.5M	Buy	92,600 +42,600	+85%	+$5.6M	﹤0.01%	2481
2021 Q1	$6.78M	Buy	+50,000	New	+$7.49M	﹤0.01%	2880
2020 Q4	–	Sell	-1,343,300	Closed	-$150M	–	5727
2020 Q3	$150M	Sell	1,343,300 -749,800	-36%	-$84.1M	0.04%	416
2020 Q2	$234M	Buy	2,093,100 +1,998,100	+2,103%	+$197M	0.07%	258
2020 Q1	$7.36M	Sell	95,000 -119,500	-56%	-$10.6M	﹤0.01%	2328
2019 Q4	$20.4M	Sell	214,500 -209,000	-49%	-$18.1M	0.01%	1845
2019 Q3	$32.3M	Sell	423,500 -160,000	-27%	-$13.3M	0.01%	1423
2019 Q2	$51.2M	Buy	583,500 +355,000	+155%	+$30.3M	0.01%	1120
2019 Q1	$20.7M	Buy	228,500 +85,100	+59%	+$7.24M	0.01%	1837
2018 Q4	$10.3M	Buy	143,400 +6,400	+5%	+$516K	﹤0.01%	2331
2018 Q3	$13.1M	Buy	137,000 +32,800	+31%	+$3.18M	﹤0.01%	2250
2018 Q2	$9.92M	Sell	104,200 -947,300	-90%	-$87.1M	﹤0.01%	2418
2018 Q1	$92.2M	Buy	1,051,500 +876,500	+501%	+$80M	0.02%	824
2017 Q4	$14.9M	Sell	175,000 -119,300	-41%	-$9.99M	﹤0.01%	2164
2017 Q3	$25.5M	Sell	294,300 -986,100	-77%	-$79.1M	0.01%	1795
2017 Q2	$98.8M	Buy	1,280,400 +52,400	+4%	+$3.72M	0.03%	775
2017 Q1	$85.2M	Sell	1,228,000 -852,800	-41%	-$57.3M	0.02%	862
2016 Q4	$123M	Buy	2,080,800 +1,212,500	+140%	+$74.8M	0.03%	648
2016 Q3	$57.6M	Sell	868,300 -1,134,900	-57%	-$70.2M	0.02%	1094
2016 Q2	$108M	Buy	2,003,200 +1,803,200	+902%	+$98.8M	0.04%	621
2016 Q1	$10.3M	Sell	200,000 -2,828,200	-93%	-$147M	﹤0.01%	2197
2015 Q4	$213M	Buy	3,028,200 +1,991,500	+192%	+$136M	0.07%	327
2015 Q3	$64.5M	Buy	1,036,700 +1,016,900	+5,136%	+$80.1M	0.02%	876
2015 Q2	$1.67M	Hold	19,800	–	–	﹤0.01%	4026
2015 Q1	$1.49M	Buy	+19,800	New	+$1.38M	﹤0.01%	4075
2014 Q4	–	Sell	-150,000	Closed	-$7.8M	–	7335
2014 Q3	$7.8M	Buy	+150,000	New	+$7.65M	﹤0.01%	2587
2013 Q4	–	Sell	-300,000	Closed	-$12.9M	–	6813
2013 Q3	$12.9M	Buy	300,000 +300	+0.1%	+$12.2K	﹤0.01%	1987
2013 Q2	$10.4M	Buy	+299,700	New	+$10.5M	﹤0.01%	2047

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Goldman Sachs's XBI Position: Q1 2026 in Review

Goldman Sachs reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 31% in Q1 2026, selling an estimated $771M and leaving 13,719,344 shares worth $1.75B. The position accounts for 0.2% of the portfolio, ranked #80.

Goldman Sachs first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.43B in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Goldman Sachs held 13,719,344 shares of State Street SPDR S&P Biotech ETF worth $1.75B as of Q1 2026.
Goldman Sachs sold 6,177,074 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $771M.
State Street SPDR S&P Biotech ETF made up 0.2% of Goldman Sachs's portfolio in Q1 2026, its #80 holding.
Goldman Sachs first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's State Street SPDR S&P Biotech ETF position peaked at $2.43B in Q4 2025.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.